Lung (includes NSCLC, SCLC, Mesothelioma)

Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug

(Forbes) Feb 14, 2018 - The fever over drugs that unleash the immune system on cancer just got even hotter.

read article

Bristol, Needing A Cancer Immunotherapy Boost, Pays Shockingly Steep Price For Nektar Drug

(STAT) Feb 14, 2018 - Bristol-Myers Squibb, seeking a new way to make its cancer immunotherapies more effective, is paying a shockingly steep — some will say desperate — price to lock up rights to an experimental drug from Nektar Therapeutics.

read article

Precipio Launches Unique Lung Cancer Monitoring Test for Therapy Resistance

(Business Insider) Feb 15, 2018 - Precipio, Inc. announced today its launch of the first lung cancer treatment resistance panel specifically for the critical mutations T790M and C797S in the EGFR gene.

read article

Merck KGaA, Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced NSCLC

(Business Insider) Feb 15, 2018 - Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose disease progressed after treatment with a platinum-containing doublet therapy.

read article

Classification Can Lead To New Ways To Diagnose, Treat Cancer

(Baylor College of Medicine) Feb 12, 2018 - A novel approach to studying cancer has enabled researchers to group about 10,000 human cancers of 32 different types into 10 classes based on the molecular pathways that drive tumor growth.

read press release

U.S., EU And Japan Health Authorities Accept Regulatory Submissions For Review Of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib

(Pfizer) Feb 12, 2018 - Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the company’s New Drug Application for lorlatinib.

read corporate press release

Exercise Before Halves Problems After Lung Cancer Surgery

(Medscape Medical News) Feb 7, 2018 - Regular exercise before lung cancer surgery cuts the risk for postoperative complications in half, according to a new analysis.

read article (free registration required)

New Analysis Finds Patients Receiving Chemotherapy for Cancer at ADCC Institutions Have Highest Survival Rates

(Alliance of Dedicated Cancer Centers) Feb 6, 2018 - Patients treated with some of the most common types of cancer with chemotherapy at Dedicated Cancer Centers have higher survival rates compared to patients treated at other types of hospitals, according to new analysis conducted by Milliman for the Alliance of Dedicated Cancer Centers.

read press release

Cancer 'Super Assassin': Huntington's Disease Molecule Can Target And Kill All Tumor Cells, Scientists Find

(Newsweek) Feb 12, 2018 - Scientists have destroyed numerous types of human cancer cells with a toxic molecule characteristic of fatal genetic illness Huntington’s disease.

read article

Merck KGaA, Pfizer's Immunotherapy Fails In Lung Cancer Trial

(Reuters) Feb 15, 2018 - Merck KGaA and Pfizer’s cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.

read article

US FDA Approves Imfinzi For Unresectable Stage III Non-Small Cell Lung Cancer

(AstraZeneca) Feb 19, 2018 - AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has approved Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).

read corporate press release

Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer

(Morningstar) Feb 22, 2018 - Daiichi Sankyo Company, Limited today announced the first patient has been dosed in a phase 1 study assessing the safety and tolerability of DS-1062, an investigational TROP2-targeting antibody drug conjugate (ADC), in patients with unresectable advanced non-small cell lung cancer (NSCLC) who are refractory to or have relapsed following standard treatment or for whom no standard treatment is available.

read article

New Therapeutic Gel Shows Promise Against Cancerous Tumors

(UNC Health Care) Feb 21, 2018 - Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner.

read press release

Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions

(MSK) Feb 21, 2018 - Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical trials published in the New England Journal of Medicine.

read article

For Latest Combo, Merck Bets $394M on Viralytics, Cancer-Fighting Viruses

(Xconomy New York) Feb 21, 2018 - The immuno-oncology combination frenzy continues. Merck this morning agreed to pay $394 million for Viralytics, an Australian developer oncolytic viruses, which could help boost the power of its cancer immunotherapy pembrolizumab (Keytruda).

read article

Merck To Buy Viralytics For $394 Million To Boost Immuno-Oncology

(Reuters) Feb 21, 2018 - U.S. drugmaker Merck & Co, already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its drug pipeline.

read article

FDA Expands Approval Of Imfinzi To Reduce The Risk Of Non-small Cell Lung Cancer Progressing

(FDA.gov) Feb 16, 2018 - The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation).

read press release

PharmaMar’s Lurbinectedin ATLANTIS Trial Design and Data In Small-Cell Lung Cancer Will Be An Oral Presentation At The Iasclc ́S Annual Meeting

(PharmaMar) Feb 20, 2018 - Dr Anna Farago, oncologist from the Massachusetts General Hospital and principal investigator of the phase III ATLANTIS clinical trial, will present the potential of lurbinectedin in small-cell lung cancer along with the main clinical data on safety and efficacy. The phase III Atlantis clinical study for recurrent small-cell lung cancer has already recruited more than two thirds of patients in more than 154 centers across 20 countries.

read corporate press release

New Technique Predicts Gene Resistance to Cancer Treatments

(Yale School of Public Health) Feb 19, 2018 - Yale School of Public Health researchers have developed a new method to predict likely resistance paths to cancer therapeutics, and a methodology to apply it to one of the most frequent cancer-causing genes.

read article

Kinase Inhibitor Larotrectinib Shows Durable Anti-tumor Abilities In Patients Of All Ages With 17 Unique Cancer Diagnoses

(MD Anderson) Feb 21, 2018 - Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses.

read press release
Next Page